A hybrid digital twin that combines mechanistic modeling with artificial intelligence could enable autonomous biomanufacturing.

Digital shadows, simpler than digital twins, can help manage nonlinear multidimensional data for process intensification.

Tandem-trapped ion mobility spectrometry can help understand what happens structurally when antibodies and antigens bind.

Kite Pharma has developed a virometry technique using nanoscale cytometry to analyze single lentiviral particles to augment Western blot.

BlueRock Therapeutics has developed a new automated system for the analytical auditing of cell therapies.

An allogeneic cell therapy company optimized their product using genome editing strategies and donor selection.

Contract manufacturer specializing in AAV promotes seamless integration for successful late-stage process development.

Capsid experts at Affinia Therapeutics hope to cut adeno-associated virus therapy manufacturing costs with plasmid engineering.

Cell-containing products can be checked for particulates arising mostly from single-use products using process simulation.

In vivo CAR T gene therapies are using viruses or lipid nanoparticles with possible off-target effects.

Manufacturers of synthetic oligonucleotide therapeutics consider Chemistry, Manufacturing, and Controls (CMC) now that products are feasible.

Manufacturers are developing platform technologies for personalized CRISPR gene-editing therapies following the Baby KJ case.

Synthetic bacteria can produce peptide chains containing non-canonical amino acids like weight loss drugs.

Cell and Gene Therapy Catapult has developed a continuous bioprocessing platform for gene therapies.

In silico tools can potentially improve yield with fewer experiments, helping accelerate development and manufacturing.

A therapeutic antibody profiler (TAP) can help manufacturers and developers study antibody sequences and developability.

Some big pharmaceutical companies are turning to enzymatic ligation from solid-phase techniques for oligonucleotides.

Scientists have installed mutations into the antibody fragment crystallizable region to aid antibody-drug conjugate manufacturing.

Light may damage antibody-drug conjugates during manufacturing; however, novel chemistries help simplify downstream processes.

Peptide ligands can remove process- and product-related impurities from gene therapies better than protein ligands.